Combination therapy incorporating Bcl-2 inhibition with Venetoclax for the treatment of refractory primary plasma cell leukemia with t (11;14)

Wilson Gonsalves, Francis K. Buadi, Shaji K Kumar

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Primary plasma cell leukemia (pPCL) is the most aggressive form of the plasma cell (PC) malignancy, multiple myeloma (MM). It has been commonly associated with the presence of a chromosome translocation involving the immunoglobulin heavy chain (IgH) locus on 14q32, that is t (11;14). Results from early phase clinical trials utilizing the selective Bcl-2 inhibitor, venetoclax, as a single agent in patients with relapsed MM have had remarkable efficacy among patients with t (11;14) abnormality. The present case demonstrates the ability of a combination regimen incorporating Bcl-2 inhibition with daratumumab, bortezomib, venetoclax, and dexamethasone to induce a rapid and very deep hematologic response in a pPCL patient with t (11;14), even in a setting of very refractory disease. This case highlights the need to further study Bcl-2 inhibition-based therapy as an option for therapy in patients with pPCL with t (11;14).

Original languageEnglish (US)
JournalEuropean Journal of Haematology
DOIs
StateAccepted/In press - Jan 1 2017

Fingerprint

Plasma Cell Leukemia
Multiple Myeloma
Immunoglobulin Heavy Chains
Proxy
Plasma Cells
Dexamethasone
Therapeutics
Chromosomes
Clinical Trials
4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)benzamide
Neoplasms

Keywords

  • Bcl-2 inhibition
  • Plasma cell leukemia
  • Venetoclax

ASJC Scopus subject areas

  • Hematology

Cite this

@article{104430f3ffea43e2b1eda00313fc06d7,
title = "Combination therapy incorporating Bcl-2 inhibition with Venetoclax for the treatment of refractory primary plasma cell leukemia with t (11;14)",
abstract = "Primary plasma cell leukemia (pPCL) is the most aggressive form of the plasma cell (PC) malignancy, multiple myeloma (MM). It has been commonly associated with the presence of a chromosome translocation involving the immunoglobulin heavy chain (IgH) locus on 14q32, that is t (11;14). Results from early phase clinical trials utilizing the selective Bcl-2 inhibitor, venetoclax, as a single agent in patients with relapsed MM have had remarkable efficacy among patients with t (11;14) abnormality. The present case demonstrates the ability of a combination regimen incorporating Bcl-2 inhibition with daratumumab, bortezomib, venetoclax, and dexamethasone to induce a rapid and very deep hematologic response in a pPCL patient with t (11;14), even in a setting of very refractory disease. This case highlights the need to further study Bcl-2 inhibition-based therapy as an option for therapy in patients with pPCL with t (11;14).",
keywords = "Bcl-2 inhibition, Plasma cell leukemia, Venetoclax",
author = "Wilson Gonsalves and Buadi, {Francis K.} and Kumar, {Shaji K}",
year = "2017",
month = "1",
day = "1",
doi = "10.1111/ejh.12986",
language = "English (US)",
journal = "European Journal of Haematology",
issn = "0902-4441",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Combination therapy incorporating Bcl-2 inhibition with Venetoclax for the treatment of refractory primary plasma cell leukemia with t (11;14)

AU - Gonsalves, Wilson

AU - Buadi, Francis K.

AU - Kumar, Shaji K

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Primary plasma cell leukemia (pPCL) is the most aggressive form of the plasma cell (PC) malignancy, multiple myeloma (MM). It has been commonly associated with the presence of a chromosome translocation involving the immunoglobulin heavy chain (IgH) locus on 14q32, that is t (11;14). Results from early phase clinical trials utilizing the selective Bcl-2 inhibitor, venetoclax, as a single agent in patients with relapsed MM have had remarkable efficacy among patients with t (11;14) abnormality. The present case demonstrates the ability of a combination regimen incorporating Bcl-2 inhibition with daratumumab, bortezomib, venetoclax, and dexamethasone to induce a rapid and very deep hematologic response in a pPCL patient with t (11;14), even in a setting of very refractory disease. This case highlights the need to further study Bcl-2 inhibition-based therapy as an option for therapy in patients with pPCL with t (11;14).

AB - Primary plasma cell leukemia (pPCL) is the most aggressive form of the plasma cell (PC) malignancy, multiple myeloma (MM). It has been commonly associated with the presence of a chromosome translocation involving the immunoglobulin heavy chain (IgH) locus on 14q32, that is t (11;14). Results from early phase clinical trials utilizing the selective Bcl-2 inhibitor, venetoclax, as a single agent in patients with relapsed MM have had remarkable efficacy among patients with t (11;14) abnormality. The present case demonstrates the ability of a combination regimen incorporating Bcl-2 inhibition with daratumumab, bortezomib, venetoclax, and dexamethasone to induce a rapid and very deep hematologic response in a pPCL patient with t (11;14), even in a setting of very refractory disease. This case highlights the need to further study Bcl-2 inhibition-based therapy as an option for therapy in patients with pPCL with t (11;14).

KW - Bcl-2 inhibition

KW - Plasma cell leukemia

KW - Venetoclax

UR - http://www.scopus.com/inward/record.url?scp=85034257251&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85034257251&partnerID=8YFLogxK

U2 - 10.1111/ejh.12986

DO - 10.1111/ejh.12986

M3 - Article

C2 - 29064593

AN - SCOPUS:85034257251

JO - European Journal of Haematology

JF - European Journal of Haematology

SN - 0902-4441

ER -